linjc16/ctgov huggingface dataset:
Posture and Pulmonary Function of Mouth-breathing Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to characterize the posture and respiratory function of mouth-breathing children.

Detailed Description
-----------------
Mouth-breathing children presents changes in stomatognathic system, which results in head projection, tension augment in scapular belt muscles and postural adaptations. Although thoracic shape and posture can influence ventilatory dynamics, we didn't find studies addressing pulmonary function of mouth-breathing children. This was a transversal study, designed to analyze the posture of mouth-breathing children, and verify the existence of correlation between posture and pulmonary volumes.

Official Title
-----------------
Posture and Pulmonary Function of Mouth-breathing Children

Conditions
-----------------
Mouth Breathing

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nasal breathing (normal subjects group) or mouth breathing (mouth-breathing group), and the age between eight (08) and twelve (12) for both groups. Exclusion Criteria: Prior physiotherapeutic treatment or in process, presence of diagnostic or report on acute or chronic pulmonary disease, neurofunctional or cognitive impairment and alteration of the osteomuscular system.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mouth Breathing<br>Children aged between 8-12 years, with clinical diagnosis of mouth breathing | |
| Nasal Breathing<br>Children aged between 8-12 years old, with normal breathing | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary function, by means of forced spirometry. |  | Within the first 30 days after recruitment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Posture, by means of photogrammetry. |  | Within the first 30 days after recruitment. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
respiration, respiratory disorders, Otolaryngology, Otorhinolaryngology, Posture
Dosage Effects of Folic Acid on Blood Folates of Honduran Women

Study Overview
=================
Brief Summary
-----------------
CDC staff at the National Center on Birth Defects and Developmental Disabilities have been working closely with a Honduras-based organization, Project Healthy Children (PNS) and the Ministry of Health, on a folic acid supplementation study among female maquila workers. Participants are divided into two groups. One group receives a 1.0 milligram pill daily while the other group receives a 5.0 milligram pill weekly. The aim of this study is to assess serum blood folate levels measured at baseline, midpoint, and endpoint of the study. Hypothesis: Folic acid (5mg)given once weekly is as effective as folic acid (1mg)given daily in raising blood folate levels.

Official Title
-----------------
Dosage Effects of Folic Acid on Blood Folates of Honduran Women

Conditions
-----------------
Spina Bifida and Anencephaly

Intervention / Treatment
-----------------
* Drug: folic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: minimum employment in factory 6 mths - Exclusion Criteria: pregnant currently consuming folic acid prior birth-defect affected pregnancy chronic disease currently taking folic acid antagonist

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: folic acid|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study for Future Families

Study Overview
=================
Brief Summary
-----------------
The Study for Future Families is a multi-center study that is recruiting pregnant women and their partners in four US cities to look for differences between cities in several measures of reproductive health. These measures include how long it took couples to conceive as well as hormone levels and semen quality in the male partners. This study is modeled after a study in four European cities so that,when complete, data on the 300 couples in each of the eight cities can be compared.

Official Title
-----------------
US Study of Semen Quality in Partners of Pregnant Women

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Pregnant women and their partners who are literate in English or Spanish and competent to complete a questionnaire whose pregnancy was conceived without medical intervention.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fertility, Hormones, Semen, Reproductive Health
Hepatitis B Vaccine Clinical Trial

Study Overview
=================
Brief Summary
-----------------
To determine the efficacy of a hepatitis vaccine in preventing hepatitis B.

Detailed Description
-----------------
BACKGROUND: Although most carriers of HBsAg are asymptomatic, a substantial proportion eventually develop chronic active hepatitis and cirrhosis. There is also overwhelming evidence that the hepatitis B virus is the single most important causative factor of hepatocellular carcinoma. Thus, mass immunization programs against HBV infection may ultimately affect not only the incidence of acute hepatitis B and the pool of chronic carriers but may also reduce the morbidity and mortality from chronic active hepatitis, cirrhosis, and hepatocellular carcinoma. Krugman and his co-workers laid the groundwork for active immunization against hepatitis B in 1970 to 1973. They discovered that a 1:10 dilution of hepatitis B infective serum lost its infectivity when boiled for one minute but retained its antigenicity and prevented hepatitis B in 70 percent of vaccinated subjects. Hilleman and his colleagues at the Merck Institute of Therapeutic Research developed a more sophisticated vaccine consisting of highly purified, formalin-inactivated HBsAg particles derived from the plasma of chronic carriers of the antigen. By 1978, data were sufficient to permit testing in a clinical trial. The first subject was inoculated in November 1978, and by October 1979, recruitment had ended. In May 1980, all trial events were reviewed and classified by an expert panel. In June 1980 the code of vaccine and placebo allocation was broken. DESIGN NARRATIVE: Randomized, double blind, fixed-sample. A total of 549 subjects were allocated to the vaccine group in which they were treated with highly purified formalin-inactivated virus subunits derived from the plasma of chronic carriers of hepatitis B. A total of 534 were allocated to the placebo group. Both groups received injections at 0, 1 month, and 6 months unless evidence of infection developed before the series was completed.

Conditions
-----------------
Hepatitis B, Hepatitis, Viral, Human, Liver Diseases

Intervention / Treatment
-----------------
* Biological: hepatitis B vaccines


Participation Criteria
=================
Eligibility Criteria
-----------------
Men at high risk for hepatitis B virus infection, 36 years of age or younger, no recent symptoms of hepatitis, blood specimen negative for HBsAg, anti-HBs and anti-HBe.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: hepatitis B vaccines|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Newborns Supplemented With Gentle-UHT Donor Milk

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effects of providing breastfeeding mothers with Gentle-UHT donor human milk (GHM) after discharge to bridge the gap during delayed onset lactation, to support an exclusive human milk diet and continued breastfeeding through the infant's first week of life. The investigators aim to determine the safety of GHM, and if GHM provided to breastfeeding mothers of outpatient babies with early weight loss will ensure babies adequately gain weight according to age-matched controls.

Official Title
-----------------
Neonates Supplemented With Gentle-UHT Donor Human Milk in the First Week of Life

Conditions
-----------------
Newborns, Breast Milk Expression

Intervention / Treatment
-----------------
* Other: Gentle-UHT donor human milk supplementation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age >36 weeks Exclusively fed human milk Age <96 hours (4 days) Exclusion Criteria: Previous admittance to the neonatal intensive care unit Supplementation of any formula

Ages Eligible for Study
-----------------
Maximum Age: 4 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Supplementation of Gentle-UHT donor milk<br>Supplementation of Gentle-UHT donor milk in addition to mother's own milk, as recommended by the health care providers. | Other: Gentle-UHT donor human milk supplementation<br>* Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born >36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight gain | Average weights compared to WHO data | 8-9 days of life | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exclusive human milk diet | Rates of infants still on an exclusive human milk diet | 8-9 days of life |
Glycemic Index of Foods

Study Overview
=================
Brief Summary
-----------------
This clinical trial will determine the effect of varying types of carbohydrates contained in milk-based beverages on the glycemic response and GI values.

Official Title
-----------------
Glycemic Index of Foods

Conditions
-----------------
Glycemic Response

Intervention / Treatment
-----------------
* Other: Nutritional drink


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and non-pregnant females 18 - 75 years of age signed consent Exclusion Criteria: Known history of chronic illnesses Current use of medication or any condition which could make participation dangerous or affect the results Unable to comply with experimental procedures Food allergies of any kind

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Group 1 - Control A<br>Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose | Other: Nutritional drink<br> <br> |
| Experimental: Group 2 - Experimental A<br>Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose | Other: Nutritional drink<br> <br> |
| Placebo Comparator: Group 3 - Control B<br>Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose | Other: Nutritional drink<br> <br> |
| Experimental: Group 4 - Experimental B<br>Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose | Other: Nutritional drink<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of Acute Exercise on Cognitive Functions

Study Overview
=================
Brief Summary
-----------------
To determine whether acute aerobic exercise versus resistance exercise effects cognitive function among older adults.

Conditions
-----------------
Cognitive Function in Elderly

Intervention / Treatment
-----------------
* Behavioral: Aerobic exercise
* Behavioral: Resistance exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Exercise at least 2 times a week Able to sign informed consent Able to perform ergometric exam Above 40 years old Exclusion Criteria: Smoking Suffering psychiatric or neurologic illness No medication for chronic illness that could effect cognitive function Problems with cognitive functioning after head trauma Long-term hospitalization within the past 3 months Inability to use computer because of vision or motor problems Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Aerobic exercise<br> | Behavioral: Aerobic exercise<br> <br> |
| Active Comparator: Resistance exercise<br> | Behavioral: Resistance exercise<br> <br> |
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of executive function |  | One month |
The Effects of Passive and Active Vibration Therapy on Grip Strength and Myoelectric Activity

Study Overview
=================
Brief Summary
-----------------
This pilot study is designed to analyze the effects of Vibration Therapy (VT) on grip strength and level of forearm contraction by measuring hand grip dynamometry and surface Electromyography (sEMG) using the BioPac sEMG and digital dynamometry devices after the application of both passive and active Vibrational Therapy (VT) using the PowerPlate.

Official Title
-----------------
The Effects of Passive and Active Vibration Therapy on Grip Strength and Myoelectric Activity

Conditions
-----------------
Strength

Intervention / Treatment
-----------------
* Procedure: Vibration with flexion
* Procedure: Vibration without flexion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participants will be Logan students, faculty and staff 18-65 yoa asymptomatic subject will be included in the study participants must complete a survey and consent form only participants that meet the criteria of the survey will be accepted in the study Exclusion Criteria: participant with any recent or past disease/injuries/trauma/fracture (i.e., arthritis, carpal tunnel, etc.) who have had joint replacements who are currently engaging in physical rehabilitation who are pregnant will be excluded from the study history of cardiovascular disease history of cancer history of epilepsy history of diabetes mellitus, or past retinal surgeries participants cannot have Chiropractic manipulation or engage in weight lifting or other extreme exercise throughout the duration of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br>Vibration with forearm flexion (active contraction) | Procedure: Vibration with flexion<br>* Vibration with forearm flexion (active contraction)<br>|
| Sham Comparator: Passive<br>Vibration without forearm flexion (passive) | Procedure: Vibration without flexion<br>* Vibration without forearm flexion (passive)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surface EMG and Grip Strength Dynamometry |  | Pre and Post treatment |
Prospective Registry of Epicardial LV Leads Placed During Cardiac Surgery Procedures

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to compare the time, risk and cost savings of 2 patient groups who receive FDA approved left ventricular pacing leads.

Detailed Description
-----------------
The purpose of this study is to: a) examine the usefulness of placing an epicardial LV lead at the time of open chest surgery in patients who are likely to benefit from a CRT system following their surgery; b) compare differences between patients who receive LV leads using the transvenous approach and those patients who receive LV leads using the epicardial approach; and c) assess the cost effectiveness of placing the LV lead via the transvenous versus the epicardial approaches.

Official Title
-----------------
Prospective Registry of Epicardial LV Leads Placed During Cardiac Surgery Procedures

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Procedure: Epicardial left ventricular lead placement
* Procedure: Transvenous left ventricular lead implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Left ventricular ejection fraction < or = 35% QRS duration greater than or = to 120ms NYHA Functional Class 3 or 4 Age > or = to 18 years Exclusion Criteria: No previous pacemaker or ICD implant No permanent atrial fibrillation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Epicardial left ventricular lead placement during a clinically indicated open chest surgery | Procedure: Epicardial left ventricular lead placement<br>* Epicardial left ventricular lead placement<br>|
| 2<br>Transvenous left ventricular lead implant during a clinically indicated CRT system implant | Procedure: Transvenous left ventricular lead implant<br>* Transvenous left ventricular lead implant<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0000 in subjects with rheumatoid arthritis (RA).

Official Title
-----------------
A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Conditions
-----------------
Inflammation, Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: NNC 0151-0000-0000
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CZ: Age between 18 and 65 years (both inclusive) A diagnosis of rheumatoid arthritis of at least three months before entry in trial Active rheumatoid arthritis (RA) Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before trial drug administration Exclusion Criteria: Known or suspected allergy to trial product or related products Body mass index (BMI) less than 18.0 or more than 38.0 kg/m2 (inclusive)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: NNC 0151-0000-0000<br>* Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period<br>|
| Placebo Comparator: B<br> | Drug: placebo<br>* Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adverse events (AEs) |  | at all scheduled visits (week 1 - week 11) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum concentrations of NNC 151-0000-0000 |  | at 48 hours after all dose administrations |